Novo Nordisk Competition -2.3% as GLP-1 Pressure Builds
Can Novo Nordisk Competition derail the obesity leader’s comeback before oral Wegovy and Medicare access have a chance to matter? Maik Kemper Editor in Chief Novo Nordisk A/S’s…
Eli Lilly Medicare Obesity: $15B Market Boom Builds
Can Medicare coverage and faster FDA plant approvals turn Eli Lilly’s obesity franchise into an even bigger profit machine? Maik Kemper Editor in Chief From my perspective, both…
Eli Lilly Record at $1 Trillion as GLP-1 Boom Lifts LLY
Can Eli Lilly’s record run keep defying gravity as GLP-1 dominance and billion-dollar dealmaking reshape Big Pharma? Maik Kemper Editor in Chief Lilly’s AI-infused commercial engine is now…
Novo Nordisk Wegovy Hits 3M U.S. Prescriptions in 22 Weeks
Has Novo Nordisk Wegovy just delivered the prescription surge that forces Wall Street to rethink the entire obesity trade? Maik Kemper Editor in Chief The oral Wegovy tablet…
Novo Nordisk Wegovy Faces a Warning in the Obesity Race
Can Novo Nordisk Wegovy regain momentum fast enough to challenge Eli Lilly before the next wave of obesity drugs resets the market? Maik Kemper Editor in Chief Oral…
Eli Lilly Acquisition Signals Pain Drug Boom Beyond GLP-1
Can Eli Lilly’s latest deal prove the company is more than a one-theme GLP-1 growth story? Maik Kemper Editor in Chief The company was focused on four main…
Eli Lilly Orforglipron Powers $19.8B Surge as Risks Rise
Can Eli Lilly Orforglipron justify Lilly’s trillion-dollar valuation as GLP-1 growth accelerates and pricing pressure starts to bite? Maik Kemper Editor in Chief Eli Lilly Orforglipron’s oral profile,…
Novo Nordisk Wegovy Falls 4.5% on Pipeline Warning
Can Novo Nordisk Wegovy keep its obesity lead if Wall Street starts caring more about the next drug than today’s sales? Maik Kemper Editor in Chief With the…
Novo Nordisk Wegovy Trial Drives 4.2% Stock Surge
Can the Novo Nordisk Wegovy Trial strengthen its obesity lead just as Wall Street starts pricing in the next GLP-1 combination wave? Maik Kemper Editor in Chief Combination…
Eli Lilly LillyDirect +5.4% as Weight Watchers Expands Access
Can Eli Lilly LillyDirect turn obesity drugs into a full-service care platform that rivals cannot easily copy? Maik Kemper Editor in Chief LillyDirect is becoming the de facto…